title: Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma.
abstract: In this retrospective study, we evaluated donor lymphocyte infusions given for relapsed (n=48) or persistent (n=15) myeloma following non-myeloablative allogeneic stem cell transplantation (Allo-SCT). Twenty-four of 63 patients (38.1%) responded: 12 patients (19.0%) with a partial response (PR) and 12 patients (19.0%) with a complete response (CR). Overall survival after donor lymphocyte infusions (DLI) was 23.6 months (1.0-50.7+). Median overall survival for non-responding patients was 23.6 months and has not been reached for the patients responding to DLI. In responders, progression-free survival after DLI was 27.8 months (1.2-46.2+). Patients with a PR had a median progression-free survival of 7.0 months, whereas patients with a CR to DLI had a median progression-free survival of 27.8 months. Major toxicities were acute graft-versus-host disease (GVHD) (38.1%) and chronic GVHD (42.9%). Seven patients (11.1%) died from treatment-related mortality. The only significant prognostic factors for response to DLI were the occurrence of acute and chronic GVHD. There was a trend towards significance for time between transplantation and DLI, and response. Donor lymphocyte infusion following non-myeloablative Allo-SCT is a valuable strategy for relapsed or persistent disease.
authors.affiliation: Department of Hematology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
authors.forename: N W C J
authors.initials: NW
authors.lastname: van de Donk
authors.forename: N
authors.initials: N
authors.lastname: Kröger
authors.forename: U
authors.initials: U
authors.lastname: Hegenbart
authors.forename: P
authors.initials: P
authors.lastname: Corradini
authors.forename: J F
authors.initials: JF
authors.lastname: San Miguel
authors.forename: H
authors.initials: H
authors.lastname: Goldschmidt
authors.forename: J A
authors.initials: JA
authors.lastname: Perez-Simon
authors.forename: M
authors.initials: M
authors.lastname: Zijlmans
authors.forename: R A
authors.initials: RA
authors.lastname: Raymakers
authors.forename: V
authors.initials: V
authors.lastname: Montefusco
authors.forename: F A
authors.initials: FA
authors.lastname: Ayuk
authors.forename: M H J
authors.initials: MH
authors.lastname: van Oers
authors.forename: A
authors.initials: A
authors.lastname: Nagler
authors.forename: L F
authors.initials: LF
authors.lastname: Verdonck
authors.forename: H M
authors.initials: HM
authors.lastname: Lokhorst
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology / Q000401:mortality; D006801:Humans; D017710:Lymphocyte Transfusion; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000401:mortality / Q000628:therapy*; D012008:Recurrence; D012074:Remission Induction; D033581:Stem Cell Transplantation / Q000401:mortality; D014184:Transplantation, Homologous; D016896:Treatment Outcome